Skip to content

Cervical spondylosis - An oral administration of classical siddha drug Kanduparangi chooranam

A prospective open labelled, single arm, non-randomized, single centric, phase II clinic trail to determine the effectiveness of kanduparangi chooranam in the management of ceganavatham (cervical spondylosis) - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/068763
Enrollment
40
Registered
2024-06-12
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M478- Other spondylosis

Interventions

Intervention1: KANDUPARANGI CHOORANAM: 3 gms (Twice a day orally with hot water before food for 45 days) Control Intervention1: NIL: NIL Control Intervention2: NIL: NIL

Sponsors

Government Siddha Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Neck pain radiating ro upper limb without numbness, giddiness and neck stiffness 2. Restricted neck movements 3. Willing for doing laboratory investigations and X-Ray imaging 4. The neck disability index score should be equal or greater than 40%

Exclusion criteria

Exclusion criteria: 1. Age: Below 20 years and above 60 years 2. Traumatic injury 3. Systemic hypertension 4. Ischemic heart diseases 5. Chronic kidney disease 6. Tuberculosis in spine 7. Secondary malignancy 8. Chronic systemic illness 9. Congenital spinal anomalies

Design outcomes

Primary

MeasureTime frame
1. The outcome is aimed at reducing pain and increasing range of movement. 2. Reduction of OSWESTRY DISABILITY INDEX score to 10 points on comparison with OSWESTRY DISABILITY INDEX score prior to the treatment.Timepoint: 45 days

Secondary

MeasureTime frame
To evaluate physicochemical, phytochemicals, biochemical analysis of clinical trial drug To evaluate the safety profile for acute and subacute toxicity of the trial drug To evaluate Antimicrobial activity of the trial drug To evaluate the pharmacological analysis of the clinical trial drug To evaluate siddha parameters and compare the (including envagaithervu) changes in ceganavatham during trial period To evaluate modern parametric changes in ceganavatham To evaluate the efficacy of Kanduparangi chooranam on ceganavatham by the biostatistical analysisTimepoint: 6 months

Countries

India

Contacts

Public ContactProf Dr T Komalavalli

Government Siddha Medical College, Palayamkottai

justusantony71@gmail.com9443090849

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026